West Pharmaceutical Servs 주식 (NYSE: WST)

에 대한 최신 뉴스 West Pharmaceutical Servs (NYSE:WST) 주식

West Pharmaceutical Servs

West Pharmaceutical Services is based in Pennsylvania, us, and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.

Equities

Large Cap

Macro Economic Events

Mid Cap

Broad U.S. Equity ETFs

Small Cap

Econ #s

Economics

Federal Reserve

Markets

Tech

ETFs

BBWI

CSCO

SPDR Dow Jones Industrial Average ETF Trust

DXCM

Citigourp Global Markets 2% Protected Notes Linked To The Djia

TEAM

TTWO

ULTA

S&amp;P 500과 나스닥 100 지수는 금요일 7일 연속 상승세를 기록했다. 주간 동안 발표된 일련의 낙관적인 경제 지표에 대응하여 위험 자산에 대한 투자 심리가 개선되면서 2023년 10월 말 이후 가장 강력한 주간 실적을 기록했다.

S&amp;P 500, 나스닥 100은 7일 연속 상승하며, 2023년 10월 이후 가장 강력한 주 기록

News

Movers

DELL

LULU

MBLY

MEDP

SMCI

STLA

이들 12개 대형주는 지난주 최악의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 에드워드 라이프사이언스(NYSE:EW)의 주가는 회사가 예상보다 나쁜 2분기 매출 실적을 보고하고 예상치보다 낮은 3분기 가이던스를 발표한 후 28.05% 급락했다. 회사는 또한 제나밸브(JenaValve)와 엔도트로닉스(Endotronix)를 인수했다. 몇몇 분석가들은 가격 전망을 대폭 낮췄다.

포드, 스텔란티스 및 델은 지난주 최악의 성과를 보인 12개 대형주 중 일부 (7월 21일부터 7월 27일)

West Pharmaceutical Services, Inc. Common Stock

West Pharmaceutical Services Inc

WEST HOLDINGS CORP by West Holdings Corp.

West Holdings Corp

WESTELL TECHS INC A NEW by Westell Technologies, Inc.

Westell Technologies Inc

WESTLIN CORP by Westlin Corp.

WESTERN URANIUM&VANADIUM by Western Uranium & Vanadium Corp.

Western Uranium & Vanadium Corp

WESTPORTS HLDGS BHD ORD by WESTPORTS HLDGS BHD

Westports Holdings Bhd

Wrapped stETH - United States Dollar

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has risen 6.9% since its last report. The company recently reported that it has 1.54 million shares sold short, which is 2.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1731087922_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 5.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Looking Into West Pharmaceutical Servs's Recent Short Interest

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has risen 6.9% since its last report. The company recently reported that it has 1.54 million shares sold short, which is 2.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.42 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730925012_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 5.31%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Peering Into West Pharmaceutical Servs's Recent Short Interest

On Thursday, West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) reported adjusted EPS of $1.85, down from $2.16 a year ago, beating the <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $1.50</a>.
The designer and manufacturer of injectable pharmaceutical packaging and delivery systems reported sales of $746.9 million, beating the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41511044/west-announces-third-quarter-2024-results-increases-fiscal-year-2024-guidance-and-declares-fourth-" rel="noreferrer noopener">consensus of $709.62 million</a>.
The Proprietary Products Segment&#8217;s sales declined by 0.2% to&nbsp;$601.4 million, and the organic net sales decline was 0.5%.
High-value products (components and devices) represented over 75% of segment net sales in the period, led by customer demand for self-injection device platforms.
Sales in the Contract-Manufactured Products Segment grew marginally by 0.4% to&nbsp;$145.5 million. Organic net sales were consistent with the third quarter of last year.
Segment performance was driven by growth in self-injection devices for obesity and diabetes, offset by a decrease in sales of healthcare diagnostic devices.
Eric M. Green, President, CEO, and Chair of the Board, commented, &#8220;We are pleased to report solid third-quarter results&#8230;This reinforces my confidence in West&#8217;s execution capabilities as we continue to deliver our proven market-led strategy and attractive long-term potential.&#8221;
Dividend: West Pharmaceutical approved the fourth quarter 2024 dividend of $0.21/share, up 5% from the $0.20/share paid in the four preceding quarters. The dividend will be paid on&nbsp;November 20 to shareholders of record as of&nbsp;November 13.
Guidance: West Pharmaceutical Services raised its fiscal year 2024 guidance on favorable currency movements.
The company expects 2024 adjusted EPS guidance of $6.55-$6.75 compared to prior guidance of $6.35-$6.65 and consensus of $6.51.
West Pharmaceutical Services forecasts 2024 sales of $2.875 billion-$2.905 billion compared to prior guidance of $2.87 billion-$2.9 billion and a consensus of $2.874 billion.
Price Action: At the last check on Thursday, WST stock was up 17.60% at $337.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/10/41516084/nvidia-chases-growth-in-india-ai-partnerships-with-reliance-infosys-wipro-expanding-into-robotics-an" target="_blank" rel="noreferrer noopener">Nvidia Chases Growth in India: AI Partnerships With Reliance, Infosys, Wipro, Expanding into Robotics And Key Industries</a>.</li>
</ul>

Earnings

Guidance

Dividends

Health Care

General

West Pharmaceutical's Q3 Performance Shows Rising Demand For Syringes, Company Boosts Annual Forecast And Dividend

U.S. stocks were mixed, with the Nasdaq Composite gaining around 100 points on Thursday.
Shares of United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) rose during Thursday's session after the company reported <a href="https://www.benzinga.com/news/earnings/24/10/41515619/delivery-giant-ups-breaks-revenue-miss-streak-after-10-quarters-stock-soars">better-than-expected quarterly EPS and sales.</a>
UPS reported consolidated revenue growth of 5.6% year-over-year to $22.2 billion, beating the consensus of $22.14 billion. Adjusted EPS was $1.76, up 12.1% YoY, above the consensus of $1.63.
United Parcel Service shares jumped 5% to $137.93 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares jumped 31.6% to $6.82 after the company said it has begun producing low volumes of its first B-sample cells and has begun shipping cells for automotive customer testing.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) gained 22.8% to $337.89 after the company reported better-than-expected third-quarter financial results.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) climbed 20.7% to $345.82 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance above estimates. Also, the company increased its fourth-quarter dividend.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) gained 18.7% to $71.65 after the company reported better-than-expected third-quarter EPS results.</li>
<li>LendingClub Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LC#NYSE">LC</a>) gained 17.7% to $14.67 after the company reported better-than-expected third-quarter financial results.</li>
<li>American Coastal Insurance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACIC#NASDAQ">ACIC</a>) surged 16.8% to $12.09 after the company provided updates on hurricane loss amounts and announced it expects a positive net income for the third quarter.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 16.5% to $248.93 following better-than-expected quarterly earnings.</li>
<li>Celestica Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) climbed 15.6% to $66.48 after the company reported better-than-expected third-quarter financial results and issued fourth-quarter revenue guidance above estimates.</li>
<li>Zai Lab Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZLAB#NASDAQ">ZLAB</a>) gained 15.2% to $33.33 after the company presented data from its ongoing Phase 1a/1b study of ZL-1310 for previously treated extensive-stage small cell lung cancer at the EORTC-NCI-AACR Symposium 2024.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) gained 14.2% to $79.66.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) surged 13.2% to $29.72 after the company announced it bagged a contract with the Space Development Agency as the prime contractor to the US Government.</li>
<li>ADT Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADT#NYSE">ADT</a>) gained 11.2% to $7.70 after the company reported better-than-expected third-quarter financial results and issued FY24 adjusted EPS above estimates.</li>
<li>Whirlpool Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WHR#NYSE">WHR</a>) rose 10% to $109.18 following a third-quarter EPS beat and guidance above consensus estimates.</li>
<li>Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) rose 9.9% to $149.00 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) gained 9.9% to $12.00 after Keybanc maintained an Overweight rating on the stock and raised its price target from $11 to $12.</li>
<li>CBRE Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRE#NASDAQ">CBRE</a>) gained 9.7% to $135.12 after the company reported better-than-expected third-quarter financial results and raised its FY24 adjusted EPS guidance above estimates.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) rose 8.2% to $629.72 following upbeat quarterly earnings.</li>
<li>Labcorp Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LH#NYSE">LH</a>) gained 7.6% to $236.52 following strong quarterly earnings.</li>
<li>Pool Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POOL#NASDAQ">POOL</a>) gained 7.5% to $377.11 following strong quarterly sales.</li>
<li>T-Mobile US, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMUS#NASDAQ">TMUS</a>) gained 4.1% to $230.00 after the company reported better-than-expected third-quarter financial results and raised its FY24 guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41516316/jim-cramer-says-he-would-not-buy-this-health-care-stock-at-this-level-wait-for-a-pullbac">Jim Cramer Says He Would Not Buy This Health Care Stock At This Level: &#8216;Wait For A Pullback&#8217;</a></li>
</ul>

Intraday Update

ACIC

ASTS

CBRE

Laboratory Corporation Of America Holdings

PEGA

PLXS

POOL

RKLB

TMUS

TSLA

VKTX

ZLAB

UPS Posts Upbeat Q3 Results, Joins Tesla, Celestica, Pool, T-Mobile And Other Big Stocks Moving Higher On Thursday

High-rolling investors have positioned themselves bullish on West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in WST often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 18 options trades for West Pharmaceutical Servs. This is not a typical pattern.
The sentiment among these major traders is split, with 83% bullish and 16% bearish. Among all the options we identified, there was one put, amounting to $25,880, and 17 calls, totaling $3,378,366.
<h3>Projected Price Targets</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $300.0 to $390.0 for West Pharmaceutical Servs during the past quarter. 
<h3>Volume &amp; Open Interest Trends</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in West Pharmaceutical Servs's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to West Pharmaceutical Servs's substantial trades, within a strike price spectrum from $300.0 to $390.0 over the preceding 30 days.
<h3>West Pharmaceutical Servs 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729777546_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WST</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$50.7</td>
<td>$47.2</td>
<td>$47.8</td>
<td>$300.00</td>
<td>$463.6K</td>
<td style="text-align: right;">804</td>
<td style="text-align: right;">694</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$45.5</td>
<td>$44.0</td>
<td>$45.5</td>
<td>$300.00</td>
<td>$455.0K</td>
<td style="text-align: right;">804</td>
<td style="text-align: right;">498</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$47.8</td>
<td>$47.7</td>
<td>$47.8</td>
<td>$300.00</td>
<td>$305.9K</td>
<td style="text-align: right;">804</td>
<td style="text-align: right;">694</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$45.5</td>
<td>$44.0</td>
<td>$45.5</td>
<td>$300.00</td>
<td>$291.2K</td>
<td style="text-align: right;">804</td>
<td style="text-align: right;">398</td>
</tr>
<tr>
<td>WST</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$45.4</td>
<td>$43.5</td>
<td>$45.4</td>
<td>$300.00</td>
<td>$290.5K</td>
<td style="text-align: right;">804</td>
<td style="text-align: right;">182</td>
</tr>
</tbody>
</table>

<h3>About West Pharmaceutical Servs</h3>
West Pharmaceutical Services is based in Pennsylvania, U.S., and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), non-glass containment solutions, and auto-injectors for injectable drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
In light of the recent options history for West Pharmaceutical Servs, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>West Pharmaceutical Servs's Current Market Status</h3>
<ul>
<li>Trading volume stands at 23,145, with WST's price down by 0.0%, positioned at $286.44.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 0 days.</li>
</ul>
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>.
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for West Pharmaceutical Servs, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

This Is What Whales Are Betting On West Pharmaceutical Servs

WIIM

West Pharmaceutical Services shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 guidance above estimates. Also, the company increased its Q4 dividend.

West Pharmaceutical Services Forecasts Full-Year 2024 Net Sales Guidance Of $2.875B-$2.905B Compared To Prior Guidance Of $2.87B-$2.9B And Consensus Of $2.874B

West Pharmaceutical Services Updates Full-Year 2024 Adjusted EPS Guidance To $6.55-$6.75 Compared To Prior Guidance Of $6.35-$6.65 And Consensus Of $6.51

West Pharmaceutical Services Approves Q4 2024 Dividend Of $0.21/Share, 5% Increase Over $0.20 Per Share Paid In Each Of The Four Preceding Quarters

West Pharmaceutical Servs Q3 2024 Adj. EPS $1.85 Beats $1.50 Estimate, Sales $746.900M Beat $709.616M Estimate

West Pharmaceutical Servs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) is preparing to release its quarterly earnings on Thursday, 2024-10-24. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect West Pharmaceutical Servs to report an earnings per share (EPS) of $1.50.
Investors in West Pharmaceutical Servs are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.22, which was followed by a 2.74% increase in the share price the next day.
Here's a look at West Pharmaceutical Servs's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.74</td>
<td>1.26</td>
<td>1.78</td>
<td>1.86</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.52</td>
<td>1.56</td>
<td>1.83</td>
<td>2.16</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-2.0%</td>
<td>3.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1729706518_0.png" alt="eps graph" />
<h3>Performance of West Pharmaceutical Servs Shares</h3>
Shares of West Pharmaceutical Servs were trading at $286.4 as of October 22. Over the last 52-week period, shares are down 12.26%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<a href="https://www.benzinga.com/quote/WST/earnings">To track all earnings releases for West Pharmaceutical Servs visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For West Pharmaceutical Servs

West Pharmaceutical Servs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) short percent of float has fallen 7.45% since its last report. The company recently reported that it has 1.44 million shares sold short, which is 2.61% of all regular shares that are available for trading. Based on its trading volume, it would take traders 3.18 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>West Pharmaceutical Servs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1728929714_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for West Pharmaceutical Servs has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing West Pharmaceutical Servs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, West Pharmaceutical Servs's peer group average for short interest as a percentage of float is 5.43%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

(WST) - Analyzing West Pharmaceutical Servs's Short Interest

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Thursday.
Shares of Build-A-Bear Workshop, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBW#NYSE">BBW</a>) rose sharply during Thursday&#8217;s session following better-than-expected <a href="https://www.benzinga.com/news/earnings/24/08/40624005/build-a-bear-workshops-q2-earnings-beat-sees-strong-improvement-in-q3-ytd-web-demand">second-quarter financial results.</a>
Build-A-Bear reported second-quarter revenue growth of 2.4% Y/Y to $111.8 million, beating the analyst consensus of $108.5 million. EPS of 64 cents (+12.3% Y/Y), beating the Wall Street view of 57 cents.
Build-A-Bear shares jumped 19.7% to $33.37 on Thursday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) shares jumped 33.2% to $42.06 following strong fourth-quarter earnings and upbeat first-quarter guidance.</li>
<li>Eos Energy Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EOSE#NASDAQ">EOSE</a>) gained 22.2% to $2.6750 after the company announced it achieved first performance milestones related to Carberus Capital Management&#8217;s investment, allowing the company to draw an additional $30 million from the delayed draw term loan.</li>
<li>Nutanix, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTNX#NASDAQ">NTNX</a>) gained 20.9% to $63.22 after the company reported better-than-expected fourth-quarter financial results and issued FY25 revenue guidance above estimates.</li>
<li>Eliem Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELYM#NASDAQ">ELYM</a>) jumped 20.1% to $7.45.</li>
<li>Iris Energy Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) gained 19.6% to $8.89 after the company announced a year-over-year increase in FY24 Bitcoin mining revenue.</li>
<li>Polestar Automotive Holding UK PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) rose 15.7% to $1.0950 after the company reported a quarter-over-quarter increase in second-quarter deliveries.</li>
<li>Best Buy Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>) gained 14.5% to $100.49 after the company reported better-than-expected quarterly financial results raised its FY25 earnings guidance.</li>
<li>iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) rose 13.2% to $77.59. iRhythm Technologies expanded global reach with the launch of Zio&#xAE; Cardiac Arrhythmia Monitoring Service in Austria, the Netherlands, Switzerland, and Spain.</li>
<li>Astera Labs, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) gained 12% to $48.75.</li>
<li>The Cooper Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COO#NYSE">COO</a>) rose 11.1% to $105.00 after the company reported better-than-expected third-quarter financial results and issued FY25 guidance above estimates. Also, Baird and Wells Fargo raised their respective price targets on the stock.</li>
<li>Kanzhun Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZ#NASDAQ">BZ</a>) gained 10.1% to $12.06 after the company announced it authorized an additional repurchase of $150 million of its shares in conjunction with its existing $200 million buyback.</li>
<li>Veeva Systems Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) climbed 8.8% to $216.85 after the company reported better-than-expected second-quarter financial results and issued FY25 adjusted EPS guidance above estimates.</li>
<li>GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) rose 8.5% to $21.62. The company issued a notice to terminate its $250 million credit facility.</li>
<li>Stevanato Group S.p.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) gained 8.3% to $21.94.</li>
<li>Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) rose 6.5% to $18.97 after B of A maintained a Buy rating on the stock and raised its price target from $30 to $31.</li>
<li>Canadian Imperial Bank of Commerce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CM#NYSE">CM</a>) gained 6% to $57.81 after the company reported better-than-expected quarterly financial results.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) rose 6% to $315.43.</li>
<li>Nokia Oyj (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOK#NYSE">NOK</a>) gained 5.8% to $4.4350 following a report suggesting that Samsung has an interest in the company&#8217;s mobile networks assets.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) gained 5.7% to $3.9127.</li>
<li>Arm Holdings plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARM#NASDAQ">ARM</a>) gained 5.6% to $132.39.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/24/08/40624754/top-2-materials-stocks-that-are-ticking-portfolio-bombs">Top 2 Materials Stocks That Are Ticking Portfolio Bombs</a></li>
</ul>

AFRM

ALAB

ELYM

EOSE

IREN

IRTC

NTNX

PSNY

STVN

VEEV

Build-A-Bear Workshop Posts Upbeat Earnings, Joins Affirm, Nutanix, Cooper Companies, Veeva Systems And Other Big Stocks Moving Higher On Thursday

The S&amp;P 500 and Nasdaq 100 indices notched their seventh consecutive day of gains on Friday, culminating in their strongest weekly performance since late October 2023 as investor sentiment toward risk assets improved in response to a string of upbeat economic indicators <a href="https://www.benzinga.com/calendars/economic">released throughout the week.</a>
Tracking these indices, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and the Invesco QQQ Trust, Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) closed with modest daily gains of 0.2% and 0.1%, respectively. For the week, the S&amp;P 500 and Nasdaq 100 soared 4% and 5.5%, marking their best weekly performances in 10 months.
The Dow Jones Index, as tracked by the SPDR Dow Jones Industrial Average ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>), closed 0.2% higher, marking its fourth straight session of gains and the best week since December 2023.
<h3 class="wp-block-heading">Wall Street Extends Winning Streak On Bullish Economic Data, Record-High Earnings</h3>
On Friday, traders welcomed a better-than-expected consumer sentiment reading from the University of Michigan, which signaled <a href="https://www.benzinga.com/news/econ-s/24/08/40419637/us-consumer-confidence-rebounds-in-august-expectations-are-subject-to-change-as-presidential-campaig">growing optimism among consumers.</a>
A day earlier, initial jobless claims for the week ending Aug. 10 surprised to the downside, indicating fewer concerns about the resilience of the labor market, while retail sales spiked more than expected by 1% on a month-over-month basis in July, marking the strongest month since January 2023.
Softer-than-anticipated inflation data for both consumers and producers released earlier this week further fueled market enthusiasm, cementing expectations for an interest rate cut from the Federal Reserve next month.
The upbeat data has tempered bets on a larger rate reduction, with market participants now leaning toward a more modest 25-basis-point cut. Market-implied probabilities for a larger 50-basis-point reduction have tumbled to 23%, according to CME Group&#8217;s FedWatch tool, as economic data signals no rush for <a href="https://www.benzinga.com/economics/macro-economic-events/24/08/40405406/interest-rate-markets-rethink-fed-strategy-as-economic-data-signals-no-rush-for-m">an overly loose monetary policy. </a>
&#8220;The latest data support our view that betting against consumers when jobs are expanding is a bad bet. Even bad weather didn&#8217;t stop them from going to the malls last month,&#8221; said Ed Yardeni, president at Yardeni Research.
The latest earnings season provides no indication of an impending recession, Yardeni said. With over 90% of S&amp;P 500 companies having reported second-quarter results, collective operating earnings per share for the index surged 10.9% year-over-year to a record high of $60.19.
<h3 class="wp-block-heading">S&amp;P 500&#8217;s Top 5 Movers On Friday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Company</td>
<td>1-day return (%)</td>
</tr>
<tr>
<td>Ulta Beauty, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ULTA#NASDAQ">ULTA</a>)</td>
<td>3.21</td>
</tr>
<tr>
<td>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>)</td>
<td>3.16</td>
</tr>
<tr>
<td>Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>)</td>
<td>3.06</td>
</tr>
<tr>
<td>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>)</td>
<td>2.67</td>
</tr>
<tr>
<td>Bath &amp; Body Works, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>)</td>
<td>2.47</td>
</tr>
</tbody>
</table>
</figure>
<h3 class="wp-block-heading">Nasdaq 100&#8217;s Top 5 Movers On Friday</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Security Name</td>
<td>1-day return (%)</td>
</tr>
<tr>
<td>Atlassian Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>)</td>
<td>5.05</td>
</tr>
<tr>
<td>DexCom, Inc.</td>
<td>3.16</td>
</tr>
<tr>
<td>PDD Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>)</td>
<td>2.90</td>
</tr>
<tr>
<td>Take-Two Interactive Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>)</td>
<td>2.43</td>
</tr>
<tr>
<td>Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>)</td>
<td>2.36</td>
</tr>
</tbody>
</table>
</figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/08/40399595/bill-ackman-cuts-chipotle-stake-right-before-stock-drop-did-billionaire-see-what-the-market-coul">Bill Ackman Cuts Chipotle Stake Right Before Stock Drop: Did Billionaire See What The Market Couldn&#8217;t?</a></li>
</ul>
Photo generated using artificial intelligence via MidJourney.

S&P 500, Nasdaq 100 Mark Seventh Straight Positive Session, Strongest Week Since October 2023: Friday's Top Movers

These twelve large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol>
<li>Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) shares plummeted 28.05%  after the company reported worse-than-expected Q2 sales results and issued Q3 guidance below estimates. The company also acquired JenaValve and Endotronix. Several analysts <a href="https://www.benzinga.com//node/39966446" target="_blank" rel="noreferrer noopener">slashed their price forecast</a>.</li>
<li>Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) shares dived 19.12% <a href="https://www.benzinga.com//node/39943178" target="_blank" rel="noreferrer noopener">following a Q2 EPS miss</a>. Several analysts <a href="https://www.benzinga.com//node/39963727" target="_blank" rel="noreferrer noopener">lowered their price target</a>.</li>
<li>STMicroelectronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) shares declined 17.60% after the company reported a Q2 EPS miss <a href="https://www.benzinga.com//node/39955407" target="_blank" rel="noreferrer noopener">and issued soft Q3 guidance</a>.</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) stock decreased <a href="https://www.benzinga.com//node/39944365" target="_blank" rel="noreferrer noopener">16.25% following soft Q3 guidance</a>.</li>
<li>Mobileye Global Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>) stock fell 14.61% last week.</li>
<li>Stellantis NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) stock lost 13.07% last week after the company reported worse-than-expected <a href="https://www.benzinga.com//node/39959183" target="_blank" rel="noreferrer noopener">first-half earnings</a>.</li>
<li>Vertiv Holdings, LLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VRT#NYSE">VRT</a>) stock fell 12.04% <a href="https://www.benzinga.com//node/39938457" target="_blank" rel="noreferrer noopener">following Q2 earnings</a>.</li>
<li>Super Micro Computer Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>) stock declined 11.68% amid a broader selloff in semiconductor stocks.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) shares declined 11.37% after the company reported a <a href="https://www.benzinga.com//node/39952104" target="_blank" rel="noreferrer noopener">Q2 earnings miss and cut its guidance</a>.</li>
<li>Dell Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) shares were down 11.26% amid a broader tech selloff.</li>
<li>United Parcel Service, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UPS#NYSE">UPS</a>) lost 10.96% value in the last week following Q2 earnings miss and <a href="https://www.benzinga.com//node/39903596" target="_blank" rel="noreferrer noopener">cutting annual outlook</a>.</li>
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) shares fell 10.89% after the company reported worse-than-expected Q2 earnings and <a href="https://www.benzinga.com//node/39961765" target="_blank" rel="noreferrer noopener">lowered its annual adjusted EPS outlook</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/07/40001614/universal-health-services-lockheed-martin-were-among-top-11-large-cap-stocks-that-shined-the-brighte" target="_blank" rel="noreferrer noopener">Universal Health Services &amp; Lockheed Martin Were Among Top 11 Large Cap Stocks That Shined The Brightest Last Week (July 21-July 27): Are The Others In Your Portfolio?</a></li>
</ul>
Photo via Shutterstock

Ford, Stellantis And Dell Are Among Top 12 Large Cap Losers Last Week (July 21-July 27): Are The Others In Your Portfolio?

Shares of Edwards Lifesciences Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EW#NYSE">EW</a>) fell sharply during Thursday's session after the company reported worse-than-expected second-quarter sales results and issued third-quarter guidance below estimates. Also, the company acquired <a href="https://www.benzinga.com/quote/EW/earnings">JenaValve and Endotronix</a>.
Edwards Lifesciences reported quarterly earnings of 70 cents per share which beat the analyst consensus estimate of 69 cents per share. The company reported quarterly sales of $1.632 billion which missed the analyst consensus estimate of $1.653 billion.
Edwards Lifesciences shares dipped 26.9% to $63.60 on Thursday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) shares jumped 85% to $1.96 after the company entered biomarker discovery market after successful retrospective ovarian cancer study yields compelling results.</li>
<li>Psyence Biomedical Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) rose 65.4% to $0.6424 after the company announced the export of nature-derived psilocybin to Australia and said a trial is projected to be initiated shortly following receipt of drug product by trial sites.</li>
<li>Salarius Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLRX#NASDAQ">SLRX</a>) jumped 60% to $3.4421.</li>
<li>Goosehead Insurance, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSHD#NASDAQ">GSHD</a>) rose 29.8% to $85.25 following upbeat second-quarter results.</li>
<li>Viking Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares gained 28.2% to $64.64 after the company reported better-than-expected second-quarter EPS results.</li>
<li>Exicure, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XCUR#NASDAQ">XCUR</a>) rose 27% to $0.5090.</li>
<li>CERo Therapeutics Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERO#NASDAQ">CERO</a>) gained 25.4% to $0.2645 after gaining around 8% on Wednesday.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) rose 25.2% to $16.72. The company announced the successful completion of its first five commercial satellites.</li>
<li>Bally&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALY#NYSE">BALY</a>) gained 24.2% to $16.80. Bally&#8217;s entered into merger agreement with affiliates of Standard General L.P.</li>
<li>Molina Healthcare, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOH#NYSE">MOH</a>) climbed 18.3% to $341.39 following better-than-expected quarterly earnings.</li>
<li>The Shyft Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHYF#NASDAQ">SHYF</a>) gained 16.4% to $13.55 following upbeat earnings.</li>
<li>Carpenter Technology Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRS#NYSE">CRS</a>) climbed 16.3% to $141.59 after the company reported better-than-expected quarterly financial results.</li>
<li>Indivior PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDV#NASDAQ">INDV</a>) rose 15.4% to $12.56 after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program.</li>
<li>Tivic Health Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIVC#NASDAQ">TIVC</a>) shares climbed 15.4% to $0.3499.</li>
<li>RPC, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RES#NYSE">RES</a>) gained 15.1% to $6.64 following upbeat earnings.</li>
<li>ServiceNow, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>) jumped 13.7% to $831.97 after the company reported better-than-expected second-quarter financial results.</li>
<li>Pegasystems Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGA#NASDAQ">PEGA</a>) rose 13.1% to $69.09 after the company reported better-than-expected second-quarter financial results.</li>
<li>Helmerich &amp; Payne, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HP#NYSE">HP</a>) climbed 12.5% to $42.46 following third-quarter results.</li>
<li>BloomZ Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMZ#NASDAQ">BLMZ</a>) gained 12.2% to $2.75 after dipping 43% on Wednesday. BloomZ recently priced its IPO at $4.30 per share.</li>
<li>Valmont Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) gained 11.1% to $300.96 following upbeat earnings.</li>
<li>Plexus Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLXS#NASDAQ">PLXS</a>) rose 10.5% to $128.36 following upbeat earnings.</li>
<li>Knight-Swift Transportation Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNX#NYSE">KNX</a>) rose 10.1% to $53.92 following second-quarter results.</li>
<li>Tyler Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TYL#NYSE">TYL</a>) gained 9.6% to $565.64 after the company reported better-than-expected second-quarter adjusted EPS and sales.</li>
<li>Mr. Cooper Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOP#NYSE">COOP</a>) rose 9.5% to $94.86 following second-quarter results.</li>
<li>Oceaneering International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OII#NYSE">OII</a>) gained 9.2% to $27.79 following strong sales.</li>
<li>RTX Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) surged 8% to $113.24 following a second-quarter earnings beat.</li>
<li>J.B. Hunt Transport Services, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBHT#NASDAQ">JBHT</a>) gained 6.1% to $173.75.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) shares dipped 60% to $1.65. 2U announced a strategic agreement with debtholders to eliminate half of debt and infuse $110 million in new capital.</li>
<li>EZFill Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EZFL#NASDAQ">EZFL</a>) tumbled 40.3% to $3.73.</li>
<li>Kindly MD, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) fell 37.5% to $2.04 after the company submitted comment to the Department of Justice regarding cannabis rescheduling.</li>
<li>Cheetah Net Supply Chain Service Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNT#NASDAQ">CTNT</a>) dipped 34% to $0.3185. Cheetah Net Supply Chain Service announced pricing of $1.49 million follow-on public offering.</li>
<li>MaxLinear, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MXL#NYSE">MXL</a>) shares fell 30.7% to $15.45 after the company reported worse-than-expected second-quarter financial results.</li>
<li>Sol-Gel Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLGL#NASDAQ">SLGL</a>) dipped 30% to $0.4750. Sol-Gel announced the signing of six exclusive license agreements to commercialize TWYNEO&#xAE; and EPSOLAY&#xAE; in Europe and South Africa.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) fell 29.7% to $9.49 after declining 10% on Wednesday.</li>
<li>Agape ATP Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) fell 27% to $0.1159.</li>
<li>Orion Group Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORN#NYSE">ORN</a>) declined 21.9% to $8.62 after the company reported worse-than-expected second-quarter financial results.</li>
<li>Ostin Technology Group Co., Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OST#NASDAQ">OST</a>) shares declined 20.3% to $0.35 after gaining around 19% on Wednesday.</li>
<li>Ribbon Communications Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RBBN#NASDAQ">RBBN</a>) tumbled 19.2% to $3.1450 after the company reported worse-than-expected quarterly revenue.</li>
<li>Ford Motor Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) shares fell 16.6% to $11.40 following a second-quarter earnings miss.</li>
<li>Hoth Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOTH#NASDAQ">HOTH</a>) fell 15.1% to $0.9103. Hoth Therapeutics shares gained around 11% on Wednesday after the company signed an agreement with LTS Therapy Systems to develop and manufacture the HT-ALZ oral film prototype for Alzheimer&#8217;s disease.</li>
<li>Garrett Motion Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTX#NASDAQ">GTX</a>) declined 13.8% to $7.86 after the company reported worse-than-expected quarterly financial results and lowered its FY24 guidance.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) shares fell 13.4% to $0.0396 after jumping over 75% on Wednesday.</li>
<li>Kaiser Aluminum Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KALU#NASDAQ">KALU</a>) declined 13.3% to $79.76 after the company reported worse-than-expected quarterly financial results.</li>
<li>Hut 8 Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUT#NYSE">HUT</a>) declined 12.8% to $15.71.</li>
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) fell 12.1% to $39.10 after the company reported worse-than-expected quarterly adjusted EPS and sales. Additionally, the company lowered its FY24 adjusted EPS outlook.</li>
<li>STMicroelectronics N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STM#NYSE">STM</a>) shares fell 12% to $34.81 after the company reported a second-quarter EPS miss and issued soft third-quarter guidance.</li>
<li>Teradyne, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) dipped 9.7% to $129.30 following soft third-quarter guidance.</li>
<li>West Pharmaceutical Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WST#NYSE">WST</a>) fell 9.5% to $292.91 after the company reported a quarterly earnings miss and cut its guidance.</li>
<li>FormFactor, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORM#NASDAQ">FORM</a>) fell 8.2% to $52.26.</li>
<li>Lululemon Athletica Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) tumbled 8.2% to $249.52 after Citigroup downgraded the stock from a Buy to a Neutral and lowered its price target from $415 to $300.</li>
<li>Robert Half Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RHI#NYSE">RHI</a>) declined 7% to $60.32 after the company reported worse-than-expected second-quarter financial results.</li>
<li>Stellantis N.V. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STLA#NYSE">STLA</a>) fell 6.8% to $18.27 following H1 results.</li>
<li>QuantumScape Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QS#NYSE">QS</a>) shares fell 6.2% to $7.01 after the company reported worse-than-expected EPS results.</li>
<li>Honeywell International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) declined 4.1% to $204.82 after the company lowered FY24 EPS guidance.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39961297/this-lululemon-analyst-is-no-longer-bullish-here-are-top-5-downgrades-for-thursday">This Lululemon Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday</a></li>
</ul>

ATPC

BALY

BLMZ

CERO

COOP

CTNT

EZFL

FORM

GSHD

HOTH

INDV

JBHT

KALU

KDLY

POAI

RBBN

SHYF

SLGL

SLNA

SLRX

TIVC

TWOU

XCUR

Why Edwards Lifesciences Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session

West Pharmaceutical Services shares are trading lower after the company reported a Q2 earnings miss and cut its guidance.

West Pharmaceutical Services Expects 2024 Adjusted EPS Of $6.35-$6.65 Versus Prior Guidance Of $7.63-$7.88 And Consensus Of $7.74

<ul>
<li>The Company is updating full-year 2024 net sales guidance to a range of $2.870 billion to $2.900 billion, compared to a prior range of $3.000 billion to $3.025 billion.
<ul>
<li>Organic net sales are now expected decrease approximately 1% to 2%.</li>
<li>Net sales guidance includes an estimated full-year 2024 headwind of approximately $5.0 million based on current foreign currency exchange rates, compared to prior guidance of approximately $8.0 million.</li>
</ul>
</li>
<li>Full-year 2024 adjusted-diluted EPS is expected to be in a range of $6.35 to $6.65, compared to prior guidance range of $7.63 to $7.88.
<ul>
<li>Full-year adjusted-diluted EPS guidance range includes an estimated headwind of approximately $0.03 based on current foreign currency exchange rates, compared to prior guidance of $0.04.</li>
<li>The updated guidance also includes EPS of $0.22 associated with first-half 2024 tax benefits from stock-based compensation.</li>
<li>For the second half of the year, our EPS guidance range assumes a tax rate of 22% and does not include potential tax benefits from stock-based compensation. Any tax benefits associated with stock-based compensation beyond those recorded in the first-half 2024 would provide a positive adjustment to our full-year adjusted-diluted EPS guidance.</li>
</ul>
</li>
<li>Full-year 2024 capital spending is expected to be $375 million, an increase from the previous estimate of $350 million.</li>
</ul>

West Pharmaceutical Services Updates Full-Year 2024 Net Sales Guidance To $2.87B-$2.9B Versus Prior Guidance Of $3B-$3.025B And Consensus Of $3.012B

West Pharmaceutical Servs Q2 2024 Adj EPS $1.52 Misses $1.74 Estimate, Sales $702.100M Miss $729.350M Estimate

West Pharmaceutical Services, Inc. 2024 Q3 - Results - Earnings Call Presentation

West Pharmaceutical Services, Inc. (WST) Q3 2024 Earnings Call Transcript

ESG 'transition' funds are an emerging trend – Here the most overweight stocks by ESG funds

In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on West Pharmaceutical Services (WST – Research ...

Comments

West Pharmaceutical Servs

뉴스

에 대한 최신 뉴스 West Pharmaceutical Servs (NYSE:WST) 주식

일요일, 8월 18, 2024

월요일, 7월 29, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌